понедельник, 31 октября 2016 г.

$40 Billion Opportunity: 3 Biotechs Poised to Dominate

$40 Billion Opportunity: 3 Biotechs Poised to Dominate


Nonalcoholic steatohepatitis has been called "the next hepatitis C" by some. Both NASH and hepatitis C are liver diseases -- and both represent huge markets for drugmakers working on cures.



from Biotech News